Login
Companies $TEVA
$42.57 +$0.00 (0.0%) After hours
TEVA PHARMACEUTICAL INDUSTRIES LTD logo

TEVA PHARMACEUTICAL INDUSTRIES LTD

tevapharm.com

What Do They Do?

Sells generic and biosimilar medicines, over-the-counter products, and treatments for neurological, respiratory and other conditions to pharmacies, wholesalers and health care providers worldwide.

How Do They Make Money?

Most revenue comes from customers buying medicines and other goods, generally on credit after shipment; licensing arrangements also generate payments for intellectual-property rights and sales-based milestones or royalties.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Sale of Goods
Sold outright

85%
FY2022: 86%
Licensing Arrangements
Licensed
3.9%
FY2022: 1.4%
Distribution
Sold outright
9.0%
FY2022: 10%
Other
Sold outright
2.5%
FY2022: 2.9%

Who Are Their Customers?

U.S. generic medicines are sold mainly to retail drug chains, mail-order distributors and wholesalers; through Anda, Teva distributes products to pharmacies, pharmacy chains, hospitals and physician offices.

Do Revenues Turn Into Profits?

Yes. It kept 8 cents of every revenue dollar as net income in FY2025 and turned 7 cents into free cash flow.

Operating income, FY2025
12% of revenue
▲ Turned profitable vs FY2024 (−$303M, −2%)
Net income, FY2025
8% of revenue
▲ Turned profitable vs FY2024 (−$1.6B, −10%)
Free cash flow, FY2025
7% of revenue
▲ +53% vs FY2024 ($749M, 5%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −2%
vs $4.5B in Q3 FY2025
Net income
▼ −46%
vs $433M in Q3 FY2025
Sale of goods share of revenue vs 87.2% in Q3 FY2025
  • Apr 29, 2026 Agreed to acquire Emalex Biosciences

Growing. Revenue grew 9% in 4 years, from $15.9B in FY2021 to $17.3B in FY2025, about 2% a year.

Japan venture sold The older report described a business venture in Japan with Takeda; the latest says Teva sold the venture, which included generic and legacy products.

Plans to divest API business The older report described sales of active pharmaceutical ingredients to third parties; the latest says Teva intends to divest that business and focus on its core strengths.

Revenue over time
Sale of Goods Licensing Arrangements Distribution Other
$20B$10B$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support